News|Articles|January 17, 2024
Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered Investment (January 2024)
Author(s)ZS Associates
Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.
Related Content
Trending on PharmExec
1
Moonwalk Biosciences Closes $70 Million Series B
2
HHS Confirms Four Senior FDA Leaders, Including Agency's First-Ever AI Deputy Commissioner
3
How Elevated Cortisol Levels Can Impact Type II Diabetes Treatments
4
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
5